+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis



Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis



International Journal of Clinical and Experimental Pathology 7(10): 6419-6429



The aim of the study is to assess the efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS) on the tamoxifen-induced endometrial lesions in breast cancer patients. PubMed and EMBASE databases were searched for eligible studies. Odds ratios were obtained to estimate the association between the LNG-IUS and tamoxifen-induced endometrial lesions. The fixed effects or random-effects model was used to combine data depending on heterogeneity. With three eligible randomized clinical trials involving 359 patients, this analysis demonstrated tamoxifen-treated breast cancer patients using the LNG-IUS derived benefit from de novo polyps prevention (P < 0.0001, OR 0.18, 95% CI: 0.08-0.42). However, the LNG-IUS only showed a trend of maintaining endometrial proliferation or secretory status (P = 0.05, OR 0.36, 95% CI 0.13-1.02) and no statistical difference in atrophic or inactive changes (P = 0.13, OR 0.24, 95% CI 0.04-1.53) or endometrial hyperplasia without atypia (P = 0.08, OR 0.20, 95% CI 0.04-1.18). The LNG-IUS didn't have an increased incidence in breast cancer recurrence (P = 0.28, OR 1.75, 95% CI: 0.64-4.80) and cancer-induced death (P = 0.71, OR 1.22, 95% CI: 0.42-3.52). Bleeding in the treatment group was statistically more frequent than that in the control group (OR 6.20, 95% CI: 2.99-12.85, P < 0.00001). This analysis verifies the efficacy of the LNG-IUS in preventing tamoxifen-induced polyps. The LNG-IUS didn't have an increased incidence in breast cancer recurrence and cancer-induced death. Long-term, large randomized studies of the LNG-IUS will be necessary to determine the benefit and risk in tamoxifen-treated breast cancer patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 054163947

Download citation: RISBibTeXText

PMID: 25400720


Related references

Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric 11(3): 252-257, 2008

Prophylactic Use of Levonorgestrel-Releasing Intrauterine System in Women With Breast Cancer Treated With Tamoxifen. Obstetrical & Gynecological Survey 68(8): 568-570, 2013

Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstetrics and Gynecology 121(5): 943-950, 2013

The role of levonorgestrel-releasing intrauterine system for endometrial protection in women with breast cancer taking tamoxifen. European Journal of Gynaecological Oncology 35(5): 492-498, 2014

Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial. Gynecologic Oncology 114(3): 452-456, 2009

Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertility and Sterility 90(1): 17-22, 2008

Cost-Effectiveness Analysis Of Using Levonorgestrel-Releasing Intrauterine System In Long-Term Contraception In Colombia. Value in Health 16(3): A74-A75, 2013

Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstetricia et Gynecologica Scandinavica 78(8): 716-721, 1999

Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 18(10): 1060-1066, 2011

Long-term use of the levonorgestrel-releasing intrauterine system. Contraception 75(6 Suppl): S161-S166, 2007

Long-term experience of a levonorgestrel-releasing intrauterine system. European Journal of Contraception and Reproductive Health Care 1(4): 319-323, 1996

Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstetrics and Gynecology 106(4): 813-817, 2005

Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstetrics and Gynecology 107(1): 207-8; Author Reply 208, 2006

Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews 2015(12): Cd007245, 2015

Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews 2009(4): Cd007245, 2009